Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for RXRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
June 30, 2026 915.00M
March 31, 2026 1.025B
December 31, 2025 1.131B
September 30, 2025 1.047B
June 30, 2025 919.15M
March 31, 2025 933.95M
December 31, 2024 1.035B
September 30, 2024 524.56M
June 30, 2024 584.45M
March 31, 2024 401.15M
December 31, 2023 463.44M
September 30, 2023 437.97M
Date Value
June 30, 2023 468.96M
March 31, 2023 430.18M
December 31, 2022 485.81M
September 30, 2022 388.03M
June 30, 2022 437.58M
March 31, 2022 493.57M
December 31, 2021 542.94M
September 30, 2021 599.03M
June 30, 2021 642.71M
March 31, 2021 215.28M
December 31, 2020 242.02M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Twist Bioscience Corp. 445.74M
Absci Corp. 246.13M
Novavax, Inc. -190.71M
Editas Medicine, Inc. 105.28M
Dyne Therapeutics, Inc. 702.15M

Shareholders Equity (Quarterly) Related Metrics